<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902927</url>
  </required_header>
  <id_info>
    <org_study_id>DVD-20948</org_study_id>
    <nct_id>NCT01902927</nct_id>
  </id_info>
  <brief_title>Modulation of Dyspnea Perception During Exercise in COPD Patients Using Attentional Distraction</brief_title>
  <acronym>DVD</acronym>
  <official_title>Modulation of Dyspnea Perception During Exercise in COPD Patients Using Attentional Distraction : a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maltais, Francois, M.D.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saey, Didier, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Louis Laviolette</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Thomas Similowski</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is a major health problem whose prevalence is&#xD;
      increasing rapidly. The gradual decrease in exercise tolerance is one of the usual&#xD;
      consequences of COPD that affects the functional independence and quality of life of&#xD;
      patients.&#xD;
&#xD;
      In COPD patients, breathlessness and muscle fatigue are the main symptoms limiting exercise.&#xD;
      Recent studies have shown that most of the physiological mechanisms of psychological factors&#xD;
      such as emotions, motivation, memory, personality, expectations, or prior experience can&#xD;
      greatly influence and modulate the perception of breathlessness. It has been proposed that&#xD;
      the attentional distraction (visual or auditory) during exercise may be associated with a&#xD;
      decrease in anxiety and shortness of breath and could improve exercise tolerance in COPD. We&#xD;
      therefore propose to study the impact of attentional strategies of distraction on the&#xD;
      perception of dyspnea and walking tolerance in patients with COPD.&#xD;
&#xD;
      The research hypotheses are:&#xD;
&#xD;
      i) Compared with exposure to a strategy of negative attentional distraction during exercise,&#xD;
      exposure to a strategy of positive attentional distraction will improve walking exercise&#xD;
      tolerance in patients with COPD;&#xD;
&#xD;
      ii) For a given level of effort, sensory perception and emotional perception will be enhanced&#xD;
      by exposure to a strategy of positive attentional distraction.&#xD;
&#xD;
      Ten subjects with moderate to severe COPD will be recruited at the Research Center of the&#xD;
      Institut Universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ). During an&#xD;
      assessment visit, we will measure complete pulmonary function, body composition and maximal&#xD;
      functional capacity during a maximal incremental test work performed on a treadmill.&#xD;
&#xD;
      During two subsequent experimental visits, and after spirometry control, participants will&#xD;
      perform a walking test performed on a treadmill at an intensity corresponding to 75% of&#xD;
      maximum effort during maximal incremental test. The test will be carried out in combination&#xD;
      with a strategy of either positive attentional distraction, neutral attentional distraction&#xD;
      or negative attentional distraction . The order of the condition will be randomized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise tolerance</measure>
    <time_frame>During each experimental visit (V2-V3-V4), from the start to the end of the exercise test (limited by symptoms of the patients). Participants will be followed for an expected period of 3 weeks (from date of randomization to the completion of the study)</time_frame>
    <description>The exercise tolerance (sec) will be defined as the time to exhaustion following a standardized constant workrate treadmill walking test corresponding to 75 % of maximal workload previously determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea perception</measure>
    <time_frame>During visit 2-3-4, from start to end of the endurance exercise test at every 90-sec intervals, up to 20 minutes. Participants will be followed for an expected period of 3 weeks (from date of randomization to the completion of the study)</time_frame>
    <description>The dyspnea intensity will be measured using a 10-point Borg scale during the exercise test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea affective perception</measure>
    <time_frame>During visit 2-3-4, from start to end of the endurance exercise test at every 90-sec intervals, up to 20 minutes. Participants will be followed for an expected period of 3 weeks (from date of randomization to the completion of the study)</time_frame>
    <description>The affective perception of dyspnea will be measured using the mutlidimensionnal dyspnea profile questionnaire (MDP), graded on a 10-point scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COPD patients will perform a constant workrate treadmill exercise test until exhaustion with positve/neutral/negative visual distraction images during the exercise test assigned in a randomized order</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Attentional distraction using IAPS protocol (standardized images)</intervention_name>
    <description>Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests</description>
    <arm_group_label>COPD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Smoking history &gt; 10 pack-years&#xD;
&#xD;
          -  Post-BD FEV1 [30-80 % predicted value]&#xD;
&#xD;
          -  Post-BD FEV1/FVC &lt; 70 %&#xD;
&#xD;
          -  Age [50-80 yrs]&#xD;
&#xD;
          -  Voorips score &lt; 9&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exacerbation &lt; 4 weeks&#xD;
&#xD;
          -  Asthma, Neoplasia, Cardiac failure, Diabetes&#xD;
&#xD;
          -  Neuromuscular limitations&#xD;
&#xD;
          -  Major depression or other psychiatric disorders&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  PaO2 &lt; 60 mmHg or oxygenotherapy&#xD;
&#xD;
          -  Involvement in a structured and regular physical activity program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Maltais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche - Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Gagnon, PhD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>2672</phone_ext>
    <email>philippe.gagnon.1@ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Didier Saey, PhD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>2614</phone_ext>
    <email>didier.saey@rea.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Gagnon, PhD</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2672</phone_ext>
      <email>philippe.gagnon.1@ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Didier Saey, PhD</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2614</phone_ext>
      <email>dider.saey@rea.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>François Maltais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Philippe Gagnon, PhD Candidate</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Exercise tolerance</keyword>
  <keyword>Dyspnea</keyword>
  <keyword>Affective distraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

